Ruxolitinib for the Treatment of Essential Thrombocythemia

Ruxolitinib for essential thrombocythemia?

Pegylated interferon for the treatment of high-risk essential thrombocythemia.

Acute Myeloid Leukemia 1339-1345 Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome having chromosome 5 and/or 7 abnormalities Hanneke M. van der Straaten, Anja van Biezen, Ronald Brand, Anton V.M.B. Schattenberg, Roel M. Egeler, Renée M. Barge, Jan J. Cornelissen, Harry C. Schouten, Gert J. Ossenkoppele, Leo F. Verdonck on behalf of the Ne...

Essential thrombocythemia

Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000. The median age at diagnosis is 65 to 70 years, but the disease may occur at any age. The female to male ratio is about 2:1. The clinical pictu...

Cost-effectiveness considerations in the treatment of essential thrombocythemia.

Factors that influence the choice of anagrelide, hydroxyurea, or interferon-alfa (IFN-alpha) for treatment of essential thrombocythemia include efficacy, toxicity, and cost. Anagrelide has the US Food and Drug Administration's approval to be used for treating patients with thrombocythemia secondary to chronic myeloproliferative disorders. In contrast, the use of IFN-alpha and hydroxyurea are co...

Emerging treatments for essential thrombocythemia

In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe a disorder characterized by permanent elevation of a platelet count to more than three times normal, hyperplasia of megakaryocytes, and the tendency for venous thrombosis and spontaneous hemorrhage. Over the last 75 years, and particularly in the past 6 years, major progress has been made in our understanding of e...